Pfizer and BioNTech stated that laboratory tests showed that...

Pfizer and BioNTech stated that laboratory tests showed that administering a third dose of the new coronavirus vaccine can neutralize the Omicron variant, while the neutralizing effect of two doses is significantly lower. Two doses of the vaccine can still prevent severe diseases. They will continue to develop a vaccine targeting the Omicron variant and expect to launch it before March next year in preparation for any need for adjustment.
Pfizer and BioNTech's pre-market stock prices surged significantly.
$BioNTech (BNTX.US)$
$Pfizer (PFE.US)$